Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| swelling agent | CHEBI_51267 | |
| oxidising agent | CHEBI_63248 | |
| reducing agent | CHEBI_63247 | |
| NMDA receptor agonist | CHEBI_64571 | |
| EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor | CHEBI_64570 | |
| flour treatment agent | CHEBI_64577 | |
| drying control chemical additive | CHEBI_51268 | |
| colon carcinoma in situ | DOID_8826 | |
| steatosis inducing agent | CHEBI_83609 | |
| THP-1 cell | CLO_0009348 | |
| hepatic steatosis inducing agent | CHEBI_83612 | |
| hepatotoxic agent | CHEBI_50908 | |
| lung carcinoma in situ | DOID_8800 | |
| intermediate coronary syndrome | DOID_8805 | |
| skin of body | UBERON_0002097 | [The organ covering the body that consists of the dermis and epidermis.] |
| Tangier disease | DOID_1388 | |
| hypolipoproteinemia | DOID_1387 | |
| abetalipoproteinemia | DOID_1386 | [A hypolipoproteinemia that is characterized by an inablility to fully absorb dietary fats, cholesterol and fat-soluble vitamins, has_physical_basis_in an autosomal recessive disorder of lipid metabolism that has material basis in mutation in the microsomal triglyceride transfer protein that catalyzes the transport of lipids (TRIGLYCERIDES; CHOLESTEROL ESTERS; PHOSPHOLIPIDS) and is required in the secretion of BETA-LIPOPROTEINS (low density lipoproteins or LDL).] |
| Fox-Fordyce disease | DOID_1381 | |
| Grignard reagent | CHEBI_51237 |